The U.S. insulin drugs and delivery devices market is projected to grow from USD 8.69 billion in 2025 to around USD 16.31 billion by 2035, registering a CAGR of 6.50%. Growth is driven by the rising prevalence of diabetes, increasing insulin adoption, and advancements in drug delivery technologies.

U.S. Insulin Drugs and Delivery Devices Market Statical Scope

The United States plays a significant role in this market, driven by its large and growing diabetic population, substantial healthcare spending, and a culture of innovation led by major industry players. Recent years have seen considerable advancements in insulin delivery device technology, transforming diabetes management.

Innovations like smart insulin pens, tubeless insulin pumps , and integrated continuous glucose monitoring (CGM) are making a significant impact. Additionally, the increasing adoption of digital health platforms and artificial intelligence -powered analytics is providing predictive insights and automated insulin dosing, further stimulating market growth.

U.S. Insulin Drugs and Delivery Devices Market Share, By Diabetes Type, 2025 (%)

• Type 2 Diabetes- Type 2 Diabetes held a share of 71%, driven by high prevalence, obesity, growing geriatric population and long-term insulin demand. There is a growing demand for smart insulin pens and automated insulin delivery systems to improve compliance.
• Type 1 Diabetes- Type 1 Diabetes leads the segment, with a share of 22%, driven by lifelong insulin dependency and continuous clinical management requirements. Insulin is the only source of managing glucose levels in patients with type 1 diabetes; therefore, there is a strong demand for insulin drugs and delivery devices.

U.S. Insulin Drugs and Delivery Devices Market Share, By End User, 2025 (%)

• Homecare Settings- Homecare Settings held the largest share of 50%, driven by strong adoption of self-administration devices and patient preference for at-home care. The increase in use of smart insulin pens and automated insulin pumps allows for enhanced remote monitoring.
• Hospitals- Hospitals segment held a share of 28%, driven by structured insulin administration in clinical settings. In hospital settings, various insulin delivery methods are employed as per the needs of patients.
• Diabetes Clinics/Centers- Diabetes Clinics/Centers segment held a share of 17%, supported by specialized diabetes management and advanced delivery devices. Furthermore, rising prevalence, favorable reimbursement, and demand for immediate care are boosting the demand for diabetes clinics.

U.S. Insulin Drugs and Delivery Devices Market Share, By Distribution Channel, 2025 (%)

• Retail Pharmacies- The Retail Pharmacies segment dominated the market with a share of 38%, driven by frequent prescription refills and preference for in-person pickups. Each retail pharmacist fills their diabetes device stocks as per the physician's preference and the patient's preferences.
• Hospital Pharmacies- The Hospital Pharmacies segment held a share of 24%, driven by inpatient treatment requirements. Growing demand for sophisticated insulin delivery systems within hospitals is further boosting the segment.
• Direct Tender/Bulk Procurement- Direct Tender/Bulk Procurement held a notable share, with a share of 20%, driven by institutional purchasing agreements. In the U.S., bulk procurement occurs through government entities like the VA, Medicaid, and major Hospital Group Purchasing Organizations due to the high cost of the products.

Top Companies in the U.S. Insulin Drugs and Delivery Devices Market

• Novo Nordisk A/S
• Eli Lilly and Company
• Sanofi
• Medtronic plc
• Insulet Corporation
• Tandem Diabetes Care, Inc.
• Ypsomed AG
• Biocon Biologics Ltd.
• Wockhardt Ltd.
• Becton
• Dickinson and Company (BD)
• F. Hoffmann-La Roche Ltd
• Abbott Laboratories (for CGM-integrated devices)
• Jiangsu Wanbang Biopharmaceuticals
• Julphar Gulf Pharmaceutical Industries
• MannKind Corporation
• Roche Diabetes Care
• Valeritas, Inc.
• Cellnovo Group SA
• Nipro Corporation
• Gerresheimer AG

Segments Covered in the Report

By Diabetes Type

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes
• Others (e.g., steroid-induced, MODY)

By End User

• Hospitals
• Diabetes Clinics/Centers
• Homecare Settings
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Sales
• Direct Tender/Bulk Procurement
• Others